IGC Pharma, Inc.
IGC · AMEX
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -5.5% | 47.6% | 129.5% | – |
| Gross Profit | $0 | $0 | -$0 | $0 |
| % Margin | 48.7% | 54.5% | -17.3% | 48.9% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -537.2% | -681.1% | -1,190.9% | -3,618.4% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -560.3% | -966.5% | -1,263% | -3,782.4% |
| EPS Diluted | -0.093 | -0.22 | -0.22 | -0.3 |
| % Growth | 57.7% | 0% | 26.7% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |